Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials

Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study

(2016) Alex Z. Fu et al.   DIABETES CARE

A Multicenter Observational Study of Incretin-based Drugs and Heart Failure

(2016) Kristian B. Filion et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

(2016) Ling Li et al.   BMJ-British Medical Journal

Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus

(2016) Guang Ning et al.   Journal of Diabetes

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

(2016) Ling Li et al.   BMJ-British Medical Journal

Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus

(2015) Shuo-Ming Ou et al.   ANNALS OF INTERNAL MEDICINE

Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes

(2015) Stephan Matthaei et al.   DIABETES CARE

Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes

(2015) Wayne H.-H. Sheu et al.   DIABETES CARE

A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes

(2015) Hae Kyung Yang et al.   ENDOCRINE JOURNAL

Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database

(2015) Gian Paolo Fadini et al.   EUROPEAN HEART JOURNAL

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis

(2015) Gianluigi Savarese et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

(2015) Faiez Zannad et al.   LANCET

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

(2015) Jennifer B. Green et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial

(2015) Weiqing Wang et al.   Journal of Diabetes

A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine

(2015) Chantal Mathieu et al.   Diabetes Therapy

A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine

(2015) Chantal Mathieu et al.   Diabetes Therapy

Trends in Prevalence and Control of Diabetes in the United States, 1988–1994 and 1999–2010

(2014) Elizabeth Selvin et al.   ANNALS OF INTERNAL MEDICINE

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials

(2014) Nayyar Iqbal et al.   Cardiovascular Diabetology

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

(2014) Benjamin M. Scirica et al.   CIRCULATION

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

(2014) Bo Ahrén et al.   DIABETES CARE

Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study

(2014) R. E. Pratley et al.   DIABETES OBESITY & METABOLISM

Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study

(2014) M. Bajaj et al.   DIABETIC MEDICINE

Sitagliptin and the risk of hospitalization for heart failure: A population-based study

(2014) Kang-Ling Wang et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials

(2014) M. Monami et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy

(2014) Judith L White et al.   BMC Endocrine Disorders

Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus 中国2型糖尿病患者使用磺脲类药物联合维格列汀可改善血糖控制且无低血糖及体重增加

(2014) Wenying Yang et al.   Journal of Diabetes

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored

(2014) John J V McMurray et al.   Lancet Diabetes & Endocrinology

Sitagliptin Use in Patients With Diabetes and Heart Failure

(2014) Daniala L. Weir et al.   JACC-Heart Failure

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus

(2014) Masato Odawara et al.   Diabetes Therapy

Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy

(2013) Anthony H. Barnett et al.   CLINICAL DRUG INVESTIGATION

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A >=52-week randomized, double-blind study

(2013) H. Yki-Jarvinen et al.   DIABETES CARE

A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

(2013) R. G. Moses et al.   DIABETES OBESITY & METABOLISM

Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function

(2013) M. Alba et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension

(2013) T. Kadowaki et al.   DIABETES OBESITY & METABOLISM

Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus

(2013) T. Kadowaki et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea

(2013) V. Lukashevich et al.   DIABETES OBESITY & METABOLISM

The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis

(2013) Paweł Kawalec et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes

(2013) J. Rosenstock et al.   DIABETIC MEDICINE

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

(2013) F. J. Lavalle-González et al.   DIABETOLOGIA

Efficacy and Safety of Linagliptin in Black/African American Patients with Type 2 Diabetes: A 6-month, Randomized, Double-blind, Placebo-controlled Study

(2013) James Thrasher et al.   Endocrine Practice

Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities-the BEGAMI study

(2013) C. Hage et al.   JOURNAL OF INTERNAL MEDICINE

Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study

(2013) W David Strain et al.   LANCET

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial

(2013) Anthony H Barnett et al.   LANCET

Cardiovascular effects of gliptins

(2013) André J. Scheen   Nature Reviews Cardiology

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus

(2013) Takashi Kadowaki et al.   Journal of Diabetes Investigation

Efficacy and Tolerability of Linagliptin Added to a Sulfonylurea Regimen in Patients With Inadequately Controlled Type 2 Diabetes Mellitus: An 18-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

(2012) Andrew J. Lewin et al.   CLINICAL THERAPEUTICS

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial

(2012) Stuart A. Ross et al.   CURRENT MEDICAL RESEARCH AND OPINION

Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin

(2012) Anthony H. Barnett et al.   CURRENT MEDICAL RESEARCH AND OPINION

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

(2012) J. B. McGill et al.   DIABETES CARE

Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2012) T. Haak et al.   DIABETES OBESITY & METABOLISM

Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial

(2012) T. Eto et al.   DIABETES OBESITY & METABOLISM

One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment

(2012) W. Kothny et al.   DIABETES OBESITY & METABOLISM

Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension

(2012) A. H. Barnett et al.   DIABETES OBESITY & METABOLISM

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

(2012) W. Kothny et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes

(2012) Vivian Fonseca et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Dipeptidyl Peptidase-4 Inhibitor

(2012) Toyoaki Murohara   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial

(2012) Robert Frederich et al.   Diabetology & Metabolic Syndrome

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks

(2012) Takashi Kadowaki et al.   Journal of Diabetes Investigation

Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

(2012) Yutaka Seino et al.   Journal of Diabetes Investigation

The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes*†

(2012) Wenying YANG et al.   Journal of Diabetes

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究)*

(2012) Adrian S. DOBS et al.   Journal of Diabetes

Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)

(2012) Richard M. Bergenstal et al.   Diabetes Therapy

Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study

(2011) Yutaka Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus

(2011) Priscilla L Hollander et al.   Diabetes & Vascular Disease Research

The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus

(2011) T. Forst et al.   DIABETES OBESITY & METABOLISM

Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes

(2011) R. R. Henry et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study

(2011) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial

(2011) V. Lukashevich et al.   DIABETES OBESITY & METABOLISM

Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study

(2011) R. Kawamori et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial

(2011) Wenying Yang et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial

(2011) Chang Yu Pan et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1

(2011) D. R. Owens et al.   DIABETIC MEDICINE

Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes

(2011) Atsunori Kashiwagi et al.   Journal of Diabetes Investigation

Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin

(2010) Kaj Stenlöf et al.   CURRENT MEDICAL RESEARCH AND OPINION

Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial

(2010) H. M. R. Pattzi et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2010) M.-R. Taskinen et al.   DIABETES OBESITY & METABOLISM

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

(2010) A. Schweizer et al.   DIABETES OBESITY & METABOLISM

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus

(2010) Masatoshi Kikuchi et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

(2010) T. Forst et al.   DIABETIC MEDICINE

Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus

(2010) Yasuhiko Iwamoto et al.   ENDOCRINE JOURNAL

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

(2010) Debora Williams-Herman et al.   BMC Endocrine Disorders

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia

(2009) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients

(2009) T. Heise et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

(2009) R. E. Pratley et al.   DIABETES OBESITY & METABOLISM

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus

(2009) K. Aaboe et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

(2009) T. Vilsbøll et al.   DIABETES OBESITY & METABOLISM

Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus

(2009) Masatoshi Kikuchi et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Efficacy and Tolerability of Vildagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy

(2009) M. Goodman et al.   HORMONE AND METABOLIC RESEARCH

Effects of Once-daily Sitagliptin on 24-h Glucose Control Following 4 Weeks of Treatment in Japanese Patients with Type 2 Diabetes Mellitus

(2009) K. Nonaka et al.   HORMONE AND METABOLIC RESEARCH

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials

(2009) M. Monami et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

(2008) P COVINGTON et al.   CLINICAL THERAPEUTICS

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

(2008) Itamar Raz et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study

(2008) R. A. DeFronzo et al.   DIABETES CARE

Efficacy and tolerability of vildagliptin in drug-nave patients with type 2 diabetes and mild hyperglycaemia

(2008) W. A. Scherbaum et al.   DIABETES OBESITY & METABOLISM

The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus

(2008) G. Garcia-Soria et al.   DIABETES OBESITY & METABOLISM

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

(2008) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*

(2008) A. J. Garber et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

(2008) Kenji Nonaka et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

(2008) Viswanathan Mohan et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

(2008) M. A. Nauck et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE